17 documents found, page 1 of 2
The Percentage of [-2]Pro-Prostate-Specific Antigen and the Prostate Health Ind...
Garrido, MM; Marta, JC; Bernardino, RM; Guerra, J; Fernandes, F; Pereira, MH; Ribeiro, R; Holdenrieder, S; Pinheiro, LC; Guimarães, JTContext.— There is a need to avoid the overdiagnosis of prostate cancer (PCa) and to find more specific biomarkers. Objective.— To evaluate the clinical utility of [−2]pro–prostate-specific antigen ([−2]proPSA) derivatives in detecting clinically significant PCa (csPCa) and to compare it with prostate-specific antigen (PSA) and with the percentage of free PSA (%fPSA). Design.— Two hundred thirty-seven men (PSA:...
The Percentage of [−2]Pro–Prostate-Specific Antigen and the Prostate Health Ind...
Garrido, MM; Marta, JC; Bernardino, RM; Guerra, J; Fernandes, F; Pereira, MH; Ribeiro, R; Holdenrieder, S; Pinheiro, LC; Guimarães, JTContext.—: There is a need to avoid the overdiagnosis of prostate cancer (PCa) and to find more specific biomarkers. Objective.—: To evaluate the clinical utility of [-2]pro-prostate-specific antigen ([-2]proPSA) derivatives in detecting clinically significant PCa (csPCa) and to compare it with prostate-specific antigen (PSA) and with the percentage of free PSA (%fPSA). Design.—: Two hundred thirty-seven men (P...
The prostate health index (PHI) density: Are there advantages over PHI or over ...
Garrido, MM; Ribeiro, RM; Pinheiro, LC; Holdenrieder, S; Guimarães, JTBackground and aims Overdiagnosis of prostate cancer (PCa) should be minimized. We wanted to evaluate the diagnostic performance of the prostate health index density (PHID) and compare it with that of the prostate health index (PHI) alone and of the prostate-specific antigen density (PSAD). Materials and methods 232 men scheduled for a prostate biopsy (prostate-specific antigen level: 2–10 µg/L), were enrolled....
Comparison of Three Assays for Total and Free PSA Using Hybritech and WHO Calib...
Garrido, MM; Marta, JC; Ribeiro, RM; Pinheiro, LC; Holdenrieder, S; Guimarães, JTBackground/Aim: Lack of interchangeability between prostate-specific antigen (PSA) assays could have a clinical impact. We compared PSA assays from different manufacturers and calibrations. Patients and Methods: A total of 233 men who underwent prostate biopsy (PSA: 2-10 ng/ml; Beckman Coulter Access® Hybritech® as reference) were enrolled. Total (tPSA) and free PSA (fPSA) were also measured using the Roche cob...
The prostate health index and the percentage of [-2]proPSA maintain their diagn...
Garrido, MM; Ribeiro, R; Pinheiro, LC; Holdenrieder, S; Guimarães, JTObjectives To evaluate the diagnostic performance of the prostate health index (PHI) and of the percentage of [-2]proPSA (%[-2]proPSA) calculated with total and free PSA from non-Beckman Coulter manufacturers (Roche and Abbott), and compare it with the fully Beckman Coulter [-2]proPSA derivatives. Methods In this study, 237 men (PSA: 2–10 μg/L) scheduled for prostate biopsy were enrolled. %[-2]proPSA and PHI we...
Are Proinflammatory Cytokines Relevant for the Diagnosis of Prostate Cancer?
Garrido, MM; Ribeiro, RM; Krüger, K; Pinheiro, LC; Guimarães, JT; Holdenrieder, S"Background/aim: Inflammation plays an important role in prostate cancer (PCa). We evaluated proinflammatory cytokines regarding differential diagnosis of PCa in men with PSA levels between 2-10 ng/ml. Patients and methods: Serum samples of 79 men (PSA 2-10 ng/ml) were analyzed for 10 proinflammatory cytokines (IL-6, IL-8, TNF-α, IFN-γ, IL-10, IL-1β, IL-2, IL-4, IL-12p70, IL-13) and results were evaluated regar...
Relevance of Circulating Nucleosomes, HMGB1 and sRAGE for Prostate Cancer Diagn...
Garrido, MM; Ribeiro, RM; Krüger, K; Pinheiro, LC; Guimarães, JT; Holdenrieder, SBackground/Aim: Evasion from cell death occurs in prostate cancer (PCa). We verified whether serum levels of cell death markers can have diagnostic value in PCa. Patients and Methods: A total of 233 men scheduled for prostate biopsy [prostate specific antigen (PSA) level: 2-10 ng/ml] were enrolled. Serum nucleosomes, nucleosomes containing the H3 histone (H3), high mobility group box 1 (HMGB1), and soluble rece...
Extracellular Vesicle Proteome in Prostate Cancer: A Comparative Analysis of Ma...
Bernardino, RM; Leão, R; Henrique, R; Pinheiro, LC; Kumar, P; Suravajhala, P; Beck, HC; Carvalho, AS; Matthiesen, RMolecular diagnostics based on discovery research holds the promise of improving screening methods for prostate cancer (PCa). Furthermore, the congregated information prompts the question whether the urinary extracellular vesicles (uEV) proteome has been thoroughly explored, especially at the proteome level. In fact, most extracellular vesicles (EV) based biomarker studies have mainly targeted plasma or serum. ...
Tratamento de Fístulas Uro-Rectais Iatrogénicas em Tumores Pélvicos no Homem: U...
Martins, FE; Martinho, D; Pinheiro, LC; Martins, NM; Ferraz, L; Xambre, L; Costa, L; Lopes, TMIntrodução: As fístulas uro-rectais (FUR) constituem uma complicação devastadora do tratamento de tumores pélvicos e um desafio cirúrgico para o cirurgião reconstrutivo. Contudo, apesar da sua crescente incidência associada a uma utilização cada vez mais frequente das diferentes modalidades não-cirúrgicas, especialmente de radioterapia, com ou sem cirurgia, para o tratamento de tumores pélvicos, a fístula urore...
Embolisation of Prostatic Arteries as Treatment of Moderate to Severe Lower Uri...
Pisco, JM; Rio Tinto, H; Pinheiro, LC; Bilhim, T; Duarte, M; Fernandes, L; Pereira, J; Oliveira, AOBJECTIVES: To evaluate the short- and medium-term results of prostatic arterial embolisation (PAE) for benign prostatic hyperplasia (BPH). METHODS: This was a prospective non-randomised study including 255 patients diagnosed with BPH and moderate to severe lower urinary tract symptoms after failure of medical treatment for at least 6 months. The patients underwent PAE between March 2009 and April 2012. Technic...